TUXARIN ER
Peakcodeine phosphate and chlorpheniramine maleate
NDAORALTABLET, EXTENDED RELEASE
Approved
Jun 2015
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Drug data last refreshed 4h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TUXARIN ER is an extended-release oral tablet combining codeine phosphate (opioid antitussive) and chlorpheniramine maleate (first-generation antihistamine) for symptomatic relief of cough and allergic rhinitis. The combination leverages codeine's cough suppression via central nervous system depression and chlorpheniramine's anticholinergic and sedating properties to address multi-symptom cold and allergy presentations. This fixed-dose combination targets patients seeking convenient, once-daily dosing for respiratory and allergic symptoms.
Peak5.2 years to LOE
As a peak-lifecycle product with minimal competitive pressure, the brand team likely maintains stable headcount focused on retention and operational efficiency rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TUXARIN ER roles center on commercial execution and market maintenance in a stable, mature product with minimal growth trajectory or clinical development. Career progression on this asset is limited; professionals should view assignments as foundational commercial experience while positioning for transition to growth-stage products pre-LOE.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.